Arsenolipids reduce butyrate levels and influence human gut microbiota in a donor-dependent way

Calatayud, Marta; Xiong, Chan; Selma‐Royo, Marta; Wiele, Tom Van de

doi:10.1016/j.ecoenv.2022.114175

Cited by 3 publications

(3 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SCFAs have many beneficial effects, stimulating insulin secretion, amplifying insulin sensitivity, and reducing inflammation and oxidative stress ( 22 – 24 ). After Cana administration, in the gut microbiota, we observed an increase in the levels of the SCFA-producing bacterium Lachnospiraceae UCG 004 , Bacteroides , and Lachnospiraceae NK4A136 group ( 25 ), which showed a negative correlation with GSP, hinting at the crucial role of SCFAs.…”

Section: Discussionmentioning

confidence: 89%

See 1 more Smart Citation

Canagliflozin alters the gut, oral, and ocular surface microbiota of patients with type 2 diabetes mellitus

Wang,

Liang,

Song

et al. 2023

Front. Endocrinol.

View full text Add to dashboard Cite

BackgroundModifications in the gut microbiota may be a crucial factor in the efficacy of canagliflozin (Cana) in managing patients with type 2 diabetes mellitus (T2DM). However, the interplay between oral and ocular surface microbiota and this treatment remains poorly explored.AimThis study aimed to assess alterations in the gut, oral, and ocular surface microbiota pre- and post-Cana treatment in patients with T2DM.MethodsIn this 30-day, controlled before-and-after study, 21 treatment-naïve patients with T2DM received sole treatment with Cana (100 mg/day), and were matched with 10 healthy controls based on gender and age. Using 16S rRNA sequencing, changes in the gut, oral, and ocular surface microbiota pre- and post-Cana treatment were assessed and compared with those of healthy controls. Concurrently, diabetes-related clinical parameters were recorded over the study period. The trial was registered in the Chinese Clinical Trial Registry (ChiCTR200034878).ResultsA noticeable shift was observed in the gut, oral, and ocular surface microbiota pre- and post-Cana treatment. The post-Cana treatment gut microbiota was more similar to that of the healthy controls. Network correlation analysis revealed that modifications in the gut, oral, and ocular surface microbiota were related to changes in clinical parameters, especially for the ocular surface microbiota.Clinical parametersA significant decrease in fasting plasma glucose (8.22 ± 2.19 vs 6.87 ± 1.09 mmol/L), glycated serum protein [291.00 (264.00, 353.00) vs 275.00 (251.00, 342.50) μmol/L], hemoglobin A1c (7.39 ± 1.18 vs 7.12 ± 1.33%), body mass index (25.32 ± 2.99 vs 24.83 ± 2.95 kg/m2), systolic blood pressure (129.05 ± 17.51 vs 123.43 ± 14.82 mmHg), and urinary creatinine [158.40 (74.75, 219.15) vs 79.70 (56.25, 138.10) μmmol/kg] levels was noted after 30-day Cana monotherapy (P < 0.05).Gut microbiomeTreatment with Cana resulted in an increase in the relative abundance of short-chain fatty acid (SCFA)-producing bacteria, particularly Lachnospiraceae UCG 004, Bacteroides, and Lachnospiraceae NK4A136 group.Oral microbiotaAfter Cana treatment, a significant increase of Prevotella and Veillonella, both of which are known to be closely associated with SCFAs, was observed.Ocular surface microbiotaPost-Cana administration, the ocular surface microbiota exhibited the most distinct changes in structure and composition. Remarkably, the majority of the increased ocular surface microbiota could produce SCFAs within the gut microbiota.ConclusionCana effectively improved the dysregulated glucose metabolism in patients with T2DM. This improvement can potentially be attributed to the restoration of balance among the gut, oral, and ocular surface microbial communities.Clinical trial registrationhttps://www.chictr.org.cn/showproj.html?proj=56487, identifier ChiCTR2000034878.

show abstract

Section: Discussionmentioning

confidence: 89%

“…T2DM, type 2 diabetes mellitus; Cana, canagliflozin. *P < 0.05, **P < 0.01, ***P < 0.001. increase in the levels of the SCFA-producing bacterium Lachnospiraceae UCG 004, Bacteroides, and Lachnospiraceae NK4A136 group (25), which showed a negative correlation with GSP, hinting at the crucial role of SCFAs.…”

Section: A B D Cmentioning

confidence: 96%

Canagliflozin alters the gut, oral, and ocular surface microbiota of patients with type 2 diabetes mellitus

Wang,

Liang,

Song

et al. 2023

Front. Endocrinol.

View full text Add to dashboard Cite

show abstract

“…Moreover, it promotes macrophage M1-type polarization by up-regulating Toll-like receptors (TLRs) expression, enhances CD4 + T-cell proliferation and differentiation into Th1 and Th17 cells, and facilitates the progression of several systemic diseases (Nejman et al 2020 ). Several studies have demonstrated that SCFAs contents in particular butyrate which has therapeutic effects on stones are significantly negatively correlated with the abundance of Fusobacterium in the intestine (Calatayud et al 2022 ; Du et al 2022 ; Kong et al 2023 ).…”

Section: Discussionmentioning

confidence: 99%

Potassium sodium hydrogen citrate intervention on gut microbiota and clinical features in uric acid stone patients

Cao,

Li,

Ding

et al. 2024

Appl Microbiol Biotechnol

View full text Add to dashboard Cite

The high recurrence rate of renal uric acid stone (UAS) poses a significant challenge for urologists, and potassium sodium hydrogen citrate (PSHC) has been proven to be an effective oral dissolution drug. However, no studies have investigated the impact of PSHC on gut microbiota and its metabolites during stone dissolution therapy. We prospectively recruited 37 UAS patients and 40 healthy subjects, of which 12 patients completed a 3-month pharmacological intervention. Fasting vein blood was extracted and mid-stream urine was retained for biochemical testing. Fecal samples were collected for 16S ribosomal RNA (rRNA) gene sequencing and short chain fatty acids (SCFAs) content determination. UAS patients exhibited comorbidities such as obesity, hypertension, gout, and dyslipidemia. The richness and diversity of the gut microbiota were significantly decreased in UAS patients, Bacteroides and Fusobacterium were dominant genera while Subdoligranulum and Bifidobacterium were poorly enriched. After PSHC intervention, there was a significant reduction in stone size accompanied by decreased serum uric acid and increased urinary pH levels. The abundance of pathogenic bacterium Fusobacterium was significantly downregulated following the intervention, whereas there was an upregulation observed in SCFA-producing bacteria Lachnoclostridium and Parasutterella, leading to a significant elevation in butyric acid content. Functions related to fatty acid synthesis and amino acid metabolism within the microbiota showed upregulation following PSHC intervention. The correlation analysis revealed a positive association between stone pathogenic bacteria abundance and clinical factors for stone formation, while a negative correlation with SCFAs contents. Our preliminary study revealed that alterations in gut microbiota and metabolites were the crucial physiological adaptation to PSHC intervention. Targeted regulation of microbiota and SCFA holds promise for enhancing drug therapy efficacy and preventing stone recurrence. Key points • Bacteroides and Fusobacterium were identified as dominant genera for UAS patients • After PSHC intervention, Fusobacterium decreased and butyric acid content increased • The microbiota increased capacity for fatty acid synthesis after PSHC intervention

show abstract

Speciation analysis and toxicity evaluation of arsenolipids—an overview focusing on sea food

Li,

Chen,

Wang

et al. 2023

Arch Toxicol

View full text Add to dashboard Cite

Arsenolipids reduce butyrate levels and influence human gut microbiota in a donor-dependent way

Cited by 3 publications

References 58 publications

Canagliflozin alters the gut, oral, and ocular surface microbiota of patients with type 2 diabetes mellitus

Canagliflozin alters the gut, oral, and ocular surface microbiota of patients with type 2 diabetes mellitus

Potassium sodium hydrogen citrate intervention on gut microbiota and clinical features in uric acid stone patients

Speciation analysis and toxicity evaluation of arsenolipids—an overview focusing on sea food

Contact Info

Product

Resources

About